Katja Weisel
Impact in
- Hematology top 0.1%
- Multiple Myeloma Research and Treatments
- Oncology top 0.5%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
Papers in
- Hematology 293
- Multiple Myeloma Research and Treatments 283
- Oncology 159
- Cancer Treatment and Pharmacology 66
- Peptidase Inhibition and Analysis 46
- CAR-T cell therapy research 31
- Co-authors
- María‐Victoria Mateos (64 shared papers)Meletios Α. Dimopoulos (91 shared papers)Vânia Hungria (21 shared papers)Pieter Sonneveld (36 shared papers)Ajay K. Nooka (25 shared papers)Andrew Spencer (26 shared papers)Antonio Palumbo (22 shared papers)Xiang Qin (17 shared papers)
- Journals
- Blood (62 papers)Journal of Clinical Oncology (57 papers)HemaSphere (19 papers)Blood Cancer Journal (9 papers)Haematologica (8 papers)
- Partner nations
- GermanyUnited StatesSpain
In The Last Decade
Katja Weisel
323 papers receiving 5.8k citations
Katja Weisel's Hit Papers
Peers
Comparison fields: 5 of 111
- Hematology 4.2k
- Oncology 2.4k
- Genetics 542
- Molecular Biology 2.6k
- Immunology 553
Countries citing papers authored by Katja Weisel
This map shows the geographic impact of Katja Weisel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katja Weisel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katja Weisel more than expected).
Fields of papers citing papers by Katja Weisel
This network shows the impact of papers produced by Katja Weisel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katja Weisel. The network helps show where Katja Weisel may publish in the future.
Co-authors
The 25 scholars most cited alongside Katja Weisel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 343 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2016 | 1086 |
| 2 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study Hit paper breakdown → | 2020 | 301 |
| 3 | 2017 | 292 | |
| 4 | 2018 | 160 | |
| 5 | 2011 | 109 | |
| 6 | 2021 | 104 | |
| 7 | 2018 | 101 | |
| 8 | 2019 | 97 | |
| 9 | 2022 | 91 | |
| 10 | 2015 | 87 | |
| 11 | 2014 | 84 | |
| 12 | 2021 | 75 | |
| 13 | 2004 | 75 | |
| 14 | 2015 | 74 | |
| 15 | 2022 | 74 | |
| 16 | 2008 | 72 | |
| 17 | 2019 | 71 | |
| 18 | 2020 | 70 | |
| 19 | 2017 | 64 | |
| 20 | 2023 | 57 |
About Katja Weisel
Katja Weisel is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 343 papers that have together received 6.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (283 papers), Protein Degradation and Inhibitors (94 papers), Cancer Treatment and Pharmacology (66 papers), Peptidase Inhibition and Analysis (46 papers), CAR-T cell therapy research (31 papers), Monoclonal and Polyclonal Antibodies Research (29 papers), Chronic Lymphocytic Leukemia Research (28 papers) and Cancer Mechanisms and Therapy (16 papers). The work is most often cited by research in Hematology (4.2k citations), Oncology (2.4k citations), Genetics (542 citations), Molecular Biology (2.6k citations) and Immunology (553 citations). Katja Weisel has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include María‐Victoria Mateos, Meletios Α. Dimopoulos, Vânia Hungria, Pieter Sonneveld, Ajay K. Nooka, Andrew Spencer, Antonio Palumbo, Xiang Qin, Jordan M. Schecter and Anita Zahlten‐Kumeli. Their work appears in journals such as Blood, Journal of Clinical Oncology, HemaSphere, Blood Cancer Journal and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.